Symbol="XFOR"
AssetType="Common Stock"
Name="X4 Pharmaceuticals Inc"
Description="X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back diseases. The company is headquartered in Boston, Massachusetts."
CIK="1501697"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="955 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="296741000"
EBITDA="-95098000"
PERatio="None"
PEGRatio="None"
BookValue="0.423"
DividendPerShare="0"
DividendYield="0"
EPS="-0.98"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.533"
ReturnOnEquityTTM="-1.892"
RevenueTTM="0"
GrossProfitTTM="3000000"
DilutedEPSTTM="-0.98"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="3.76"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="53.87"
PriceToBookRatio="1.041"
EVToRevenue="50.06"
EVToEBITDA="-0.252"
Beta="0.244"
num_52WeekHigh="2.575"
num_52WeekLow="0.65"
num_50DayMovingAverage="1.969"
num_200DayMovingAverage="1.453"
SharesOutstanding="158685000"
DividendDate="2019-03-14"
ExDividendDate="None"
symbol="XFOR"
open="1.87"
high="1.90"
low="1.77"
price="1.82"
volume="1782976.00"
latest_trading_day="2023-07-21"
previous_close="1.87"
change="-0.05"
change_percent="-2.6738%"
aroon_positive_momentum_days="86"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="86"
Volume_recent_avg="3054136"
Change_recent_avg="0.01"
Delta_recent_avg="0.15"
Variance_recent_avg="0.07"
Change_ratio_recent_avg="0.1"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="86"
Aroon_momentum_negative="14"
image_negative_thumbnail_id_1="157"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0019.jpeg"
image_negative_thumbnail_id_2="1162"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0196.jpeg"
image_neutral_thumbnail_id_1="549"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0050.jpeg"
image_neutral_thumbnail_id_2="575"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0024.jpeg"
image_positive_thumbnail_id_1="629"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0079.jpeg"
image_positive_thumbnail_id_2="701"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0007.jpeg"
image_professor_thumbnail_id_1="1167"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0001.jpeg"
image_professor_thumbnail_id_2="1201"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0035.jpeg"
